CD8 TIL cell therapy - Aventis Gencell

Drug Profile

CD8 TIL cell therapy - Aventis Gencell

Latest Information Update: 09 Jul 2002

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Aventis Gencell
  • Class Cell therapies
  • Mechanism of Action CD8 antigen stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Graft-versus-host disease; Renal cancer

Most Recent Events

  • 11 Jan 2000 A study has been added to the therapeutic trials and adverse events sections
  • 24 Dec 1999 Rhône-Poulenc Rorer Gencell is now Aventis Gencell
  • 31 Aug 1998 A study has been added to the therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top